id	author	title	date	pages	extension	mime	words	sentence	flesch	summary	cache	txt
dpc-3026	Boziou, Maria; Dionyssiou, Dimitrios; Dionyssopoulos, Dimitrios; Lazaridou, Elizabeth; Lallas, Aimilios; Apalla, Zoe	Can Cemiplimab Become a Life-Changer in Xeroderma Pigmentosum?	2023	5	.pdf	application/pdf	2986	115	74	2023;13(3):e2023160 1 Can Cemiplimab Become a Life-Changer in Xeroderma Pigmentosum? Maria Boziou1, Dimitrios Dionyssiou2, Dimitrios Dionyssopoulos3, Elizabeth Lazaridou1, Aimilios Lallas4, Zoe Apalla1 1 Second Dermatology Department, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece 2 Department of Plastic Surgery, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece 3 Department of Medical Oncology, Faculty of Medicine, School of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece 4 First Dermatology Department, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece Key words: immune checkpoint inhibitors, cemiplimab, xeroderma pigmentosum, squamous cell carcinoma, melanoma Citation: Boziou M, Dionyssiou D, Dionyssopoulos D, Lazaridou E, Lallas A, Apalla Z. Upon clinical examination, apart from extensive freckling and numerous actinic keratoses, we identified two atypical melanocytic lesions compatible with melanoma and multiple basal (BCC) and squamous cell carcinomas (SCC) (Figure 1).	cache/dpc-3026.pdf	txt/dpc-3026.txt